1 résultat
CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
Auteurs / Authors
G. Goss, G.E. Darling, V. Westeel, K. Nakagawa, B. Massuti Sureda, F. Perrone, S-A. McLachlan, J.H. Kang, Y-L. Wu, A-M.C. Dingemans, R. Dziadziuszko, M. Okada, L. Greillier, C. Audigier-Valette, S. Sugawara, E. Nadal, A. Catino, M.R. Stockler, K. Ding, C. O’Callaghan
Journal / Conference
ESMO
Année / Year
2024
PMID / session
Etude IFCT